Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 3—March 2013
Research

Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010

Rebekah H. Borse1, Sundar S. Shrestha, Anthony E. Fiore, Charisma Y. Atkins, James A. Singleton, Carolyn Furlow, and Martin I. MeltzerComments to Author 
Author affiliations: Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 10

Results of sensitivity analyses to determine effects of assumed percentages of subclinical cases of influenza A(H1N1)pdm09 virus infection*

Assumed proportion subclinical cases No. clinical cases prevented (range)
50% 891,682 (651,567–1,135,546)
30% (base estimate) 1,029,157 (712,908–1,458,930)
0% 1,133,734 (759,341–1,706,714)

*Data reflect calculations made for scenario 8 by changing assumed percentages of subclinical cases of influenza.

Main Article

1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.

Page created: February 12, 2013
Page updated: February 12, 2013
Page reviewed: February 12, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external